This overturns decades of macrophage-centric thinking and identifies a previously undescribed pro-fibrotic neutrophil population in silicotic lungs, which could refine future treatments.

A new study from the Hudson Institute of Medical Research shows that airway epithelial cells—not immune cells—drive early inflammation and fibrosis in silicosis by activating the NLRP3 protein when exposed to silica particles.

Removing NLRP3 specifically from epithelial cells in experimental models dramatically reduced early inflammation, blocked recruitment of pro-fibrotic immune cells, and decreased long-term lung damage, shifting the therapeutic target to the airway epithelium.

The findings support a precision-medicine approach and pave the way for therapies that intervene at the disease’s origin in the airway epithelium, potentially reducing the need for oxygen therapy or transplantation.

The research points to inhaled or locally delivered drugs that target epithelial NLRP3 as a promising precision therapy to halt disease progression before irreversible scarring, avoiding systemic immune suppression.

In addition, eliminating epithelial NLRP3 could prevent the recruitment of pro-fibrotic immune cells and lessen long-term lung damage.

Engineered stone exposure is driving a global rise in silicosis, with prevalence up 91.4% and incidence up 64.6% from 1990 to 2019, and high-dose exposures can trigger rapid disease progression in months.

Hudson Institute emphasizes the global relevance of preventing and treating silicosis, supported by the Medical Research Future Fund, aiming to deliver real therapeutic options for affected workers.

The work highlights a worldwide urgency to address silica-related lung disease and translate findings into accessible therapies for workers exposed to dangerous dust.

Overall, the study reframes silicosis as an epithelial-driven disease with a clear molecular target, offering a path to earlier intervention and better outcomes.

The approach avoids broad immune suppression by focusing on local delivery to the airway, aligning with precision medicine goals.

If successful, these therapies could reduce reliance on oxygen therapy or lung transplantation for silicosis patients in the future.